Pilot study to validate a computer-based clinical decision support system for dyslipidemia treatment (HTE-DLP)

Atherosclerosis. 2013 Dec;231(2):401-4. doi: 10.1016/j.atherosclerosis.2013.09.029. Epub 2013 Oct 18.


Pilot study to validate a Computerized Decision Support Systems (CDS) (HTE-DLP) for improving treatment of hyperlipidemia.

Methods: HTE-DLP was programmed to offer automatic specific reminders for lipid treatment. Seventy-seven patients with high cardiovascular risk were randomized. 10 expert physicians in cardiovascular-risk management were recruited. We assessed number of patients at LDL <70 mg/dl after 12 weeks of treatment.

Results: A greater proportion of intervention group reached the LDL-C <70 mg/ml [55.0% vs 12.5%, p = 0.003; OR: 3.26 IC (1.16-9.15)]. "High potency statins" and combined therapy were used more frequently in the intervention group than the control group (p = 0.001). Seven adverse effects were documented in the intervention group and two in the control group. An acceptable relationship was observed with regard to costeffectiveness in the intervention group. Physicians expressed good agreement with HTE-DLP (86.1%) and comfortable ease-of-use (85%).

Conclusions: Use of a CDSS in high-risk cardiovascular patients resulted in a significant reduction in LDL-C levels.

Keywords: CDSS; Computerized decision support system; Hyperlipidemia.

Publication types

  • Randomized Controlled Trial
  • Validation Study

MeSH terms

  • Aged
  • Atherosclerosis / economics
  • Atherosclerosis / therapy
  • Cardiology / methods
  • Cardiology / standards
  • Cholesterol, LDL / blood
  • Cost-Benefit Analysis
  • Decision Support Systems, Clinical / economics*
  • Dyslipidemias / economics
  • Dyslipidemias / therapy*
  • Female
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / economics
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
  • Male
  • Middle Aged
  • Pilot Projects
  • Treatment Outcome
  • Triglycerides / blood
  • User-Computer Interface


  • Cholesterol, LDL
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Triglycerides